We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly Gets FDA Approval for New Oral Tablets for Migraine
Read MoreHide Full Article
Eli Lilly & Company (LLY - Free Report) announced that the FDA has approved lasmiditan for the treatment of acute migraine headaches, with or without aura, in adults. Lasmiditan, an oral 5-HT1F agonist, is the first and only FDA-approved medicine in this class of migraine drugs. Lasmiditan will be marketed by the trade name of Reyvow and will be available in oral doses of 50 mg, 100 mg, and 200 mg, once launched.
The new drug application for Reyvow was based on data from two phase III studies, SAMURAI and SPARTAN. Both the studies met the efficacy endpoints. Data from the studies showed that treatment with Reyvow led to pain freedom and freedom from most bothersome symptoms of migraine at two hours after administration of Reyvow compared to placebo.
Please note that lasmiditan was added to Lilly’s portfolio with the 2017 acquisition of CoLucid Pharmaceuticals.
Year to date, Lilly’s shares have declined 6.3% compared with the industry’s decrease of 0.8%.
Reyvow’s approval has boosted Lilly’s portfolio of pain medicines, which also includes recently launched, Emgality, its CGRP antibody, for the preventive treatment of migraine. Emgality was launched in the United States in September last year. Emgality was approved in the United States for another indication, episodic cluster headache in June 2019. Emgality, a once-monthly, self-administered, subcutaneous 120 mg injection, could emerge as a significant contributor to long-term growth at Lilly. However, it faces strong competition from Teva (TEVA - Free Report) and Amgen’s (AMGN - Free Report) CGRPs, Ajovy and Aimovig, respectively, which were also approved in 2018.
Lilly’s pain portfolio also includes tanezumab, which is being evaluated, in collaboration with Pfizer, Inc. (PFE - Free Report) . Lilly expects to file a NDA for tanezumab for treating osteoarthritis pain next year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Lilly Gets FDA Approval for New Oral Tablets for Migraine
Eli Lilly & Company (LLY - Free Report) announced that the FDA has approved lasmiditan for the treatment of acute migraine headaches, with or without aura, in adults. Lasmiditan, an oral 5-HT1F agonist, is the first and only FDA-approved medicine in this class of migraine drugs. Lasmiditan will be marketed by the trade name of Reyvow and will be available in oral doses of 50 mg, 100 mg, and 200 mg, once launched.
The new drug application for Reyvow was based on data from two phase III studies, SAMURAI and SPARTAN. Both the studies met the efficacy endpoints. Data from the studies showed that treatment with Reyvow led to pain freedom and freedom from most bothersome symptoms of migraine at two hours after administration of Reyvow compared to placebo.
Please note that lasmiditan was added to Lilly’s portfolio with the 2017 acquisition of CoLucid Pharmaceuticals.
Year to date, Lilly’s shares have declined 6.3% compared with the industry’s decrease of 0.8%.
Reyvow’s approval has boosted Lilly’s portfolio of pain medicines, which also includes recently launched, Emgality, its CGRP antibody, for the preventive treatment of migraine. Emgality was launched in the United States in September last year. Emgality was approved in the United States for another indication, episodic cluster headache in June 2019. Emgality, a once-monthly, self-administered, subcutaneous 120 mg injection, could emerge as a significant contributor to long-term growth at Lilly. However, it faces strong competition from Teva (TEVA - Free Report) and Amgen’s (AMGN - Free Report) CGRPs, Ajovy and Aimovig, respectively, which were also approved in 2018.
Lilly’s pain portfolio also includes tanezumab, which is being evaluated, in collaboration with Pfizer, Inc. (PFE - Free Report) . Lilly expects to file a NDA for tanezumab for treating osteoarthritis pain next year.
Lilly currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>